Riskpilot← Back to searchSign inGet full accessNeores AB
ABActiveOrg 5569549826Jaktstigen 21Research and experimental development on natural sciences and engineering · NACE 7210Est. 20130 employees
Revenue 2024
SEK 1,1M
+4% vs 2023
EBITDA margin
29.9%
-2% vs 2023
Equity ratio
97.2%
Financial strength
Net profit 2024
SEK 262K
-2% vs 2023
| Revenue | SEK 1,1M | +4% |
| EBITDA | SEK 330K | -2% |
| Net profit | SEK 262K | -2% |
| Total assets | SEK 1,1M | +0% |
| Equity | SEK 1,1M | +32% |
| Employees | 0 | — |
Legal name
Neores AB
Org number
5569549826
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
17 december 2013
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Drevhammar, Thomas Emanuel Nilsson, Kjell Ove
Company purpose
Bolaget ska bedriva konsultation, konstruktion, formgivning samt utveckling inom medicin och medicinteknik samt därmed förenlig verksamhet.
Address
Jaktstigen 21
Email
thomas.drevhammar@icloud.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 857 | 854 | 953 | 1 064 | 1 102 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 468 | 386 | 407 | 336 | 330 |
| Depreciation & amort. | −147 | −55 | −0 | −0 | −0 |
| EBIT | 321 | 331 | 407 | 336 | 330 |
| Net financials | −12 | — | — | — | — |
| Profit before tax | 309 | 330 | 406 | 336 | 330 |
| Tax | −66 | −73 | −84 | −69 | −68 |
| Net profit | 243 | 257 | 322 | 267 | 262 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 655 | 951 | 1 365 | 1 107 | 1 111 |
| Equity | 570 | 828 | 1 150 | 817 | 1 080 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 85 | 124 | 215 | 290 | 31 |
| Total debt | 85 | 124 | 215 | 290 | 31 |
EBITDA margin
29.9%
This company
15.8%
Market median
+89% vs market
20202024
Equity ratio
97.2%
This company
38.2%
Market median
+154% vs market
20202024
Return on equity
24.3%
This company
18.4%
Market median
+32% vs market
20202024
Net profit margin
23.8%
This company
8.1%
Market median
+194% vs market
20202024
Asset turnover
0.99×
This company
1.12×
Market median
+12% vs market
20202024
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
TE Chief Executive Officer | Chief Executive Officer | 2022 |
PG | Audit | 2024 |
| Former (1) | ||
GN | Audit | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 91% | 91% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Northern Critical Care AB
Neores AB Board members of Neores AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Emanuel Drevhammar | Chief Executive Officer | 0 companies |
| Gösta Niklas Malmgren | Audit | 0 companies |
| Per Gustav Pelle Lindblad | Audit | 0 companies |
| Toby Foster | Board of Directors | 0 companies |
| Lena Cecilia Kajland Wilén | Chairman | 0 companies |
| Kjell Ove Nilsson | Board of Directors | 0 companies |